Clinical Trials Browser

Phase 1/2 × Withdrawn × tandutinib × Clear all

NCT00297921 2013-11-06

A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute